Cargando…
Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
Heart failure (HF) accounts for a tremendous burden on health care systems and the society. Since the landmark PARADIGM-HF trial, sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitor (ARNI) showed superiority to enalapril in patients with HF with reduced ejection...
Autores principales: | Cruz Rodriguez, Jose B., Cu, Cameron, Siddiqui, Tariq |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039652/ https://www.ncbi.nlm.nih.gov/pubmed/33850915 http://dx.doi.org/10.21037/atm-20-4038 |
Ejemplares similares
-
Narrative review of pharmacotherapy for transthyretin cardiac amyloid
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021) -
Management of left ventricular thrombus: a narrative review
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021) -
Editorial for “Heart Failure Update and Advances in 2021”
por: Mukherjee, Debabrata, et al.
Publicado: (2021) -
Updates in pharmacotherapy of heart failure with reduced ejection fraction
por: Espinoza, Clifton, et al.
Publicado: (2021) -
Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction
por: Paz, Pablo Alejandro, et al.
Publicado: (2021)